GlobeNewswire Inc | Nov 4, 2020 07:00AM EST

November 04, 2020

CRESSKILL, N.J. and JERUSALEM, Nov. 04, 2020 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (BrainsWay or the Company), a global leader in the advanced noninvasive treatment of brain disorders, today announced that it will report its third quarter 2020 financial results and operational highlights before the open of the U.S. financial markets onWednesday, November 18, 2020. The Company will host a conference call and webcast at 8:30 AM Eastern Timeto discuss the results and provide an update on business operations.

Conference Call Dial-In & Webcast Information:

Date: Wednesday, November 18, 2020Time: 8:30 AM Eastern TimeUnited States: 877-407-3982Israel: 1 809 406 247International: 201-493-6780Conference ID: 13711444Webcast: http://public.viavid.com/index.php?id=141762

The conference call will be broadcast live and will be available for replay for 30 days on the Companys website, https://investors.brainsway.com/financial-calendar. Please access the Companys website at least 10 minutes ahead of the conference call to register.

About BrainsWayBrainsWay is a commercial stage medical device company focused on the development and sale of non-invasive neurostimulation products using the Companys proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology. The Company received marketing authorization from the U.S. Food and Drug Administration (FDA) for its products for a variety of patient populations, including in 2013 for patients with major depressive disorder (MDD), in 2018 for patients with obsessive-compulsive disorder (OCD), and in 2020 for patients with smoking addiction. BrainsWay is currently conducting clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders. To learn more, please visitwww.brainsway.com

Forward Looking StatementsAny forward-looking statements are subject to risks and uncertainties such as those described in BrainsWay's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.

Contacts:BrainsWayJudy HuberSVP and Chief Financial OfficerJudy.huber@brainsway.com

Investors:Bob YedidLifeSci Advisors646-597-6989Bob@LifeSciAdvisors.com